Effect of coordinated therapeutic assays using C. parvum, interferon and arginine butyrate on spontaneous disease and survival of AKR mice
| Autor: | Italina Cerutti, Charles Chany, Bertrand Mace |
|---|---|
| Rok vydání: | 1983 |
| Předmět: |
Cancer Research
Lymphoma Microgram medicine.medical_treatment Butyrate Biology Arginine Mice Mice Inbred AKR Immune system Interferon medicine Neoplasm Animals Propionibacterium acnes Survival rate Leukemia Experimental Immunotherapy medicine.disease Molecular biology Killer Cells Natural Leukemia Butyrates Oncology Immunology Female Interferons medicine.drug |
| Zdroj: | International journal of cancer. 32(3) |
| ISSN: | 0020-7136 |
| Popis: | AKR mice, known to develop spontaneous leukemia in almost 100% of cases, were studied throughout their life-span. Different treatments combining a potent immune stimulator, Corynebacterium parvum (CP), with interferon (IFN) and arginine butyrate were initiated at the 15th week of life. In a preliminary series of experiments, CP (200 micrograms), IFN (20,000 units) and butyrate 50 mM) were employed in a well-defined chronological order. In controls, the mean survival time (MST) was 35.17 +/- 1.67 weeks and the final survival rates was 0/50 mice for all experiments. Only CP associated with arginine butyrate significantly augmented the MST (42.5 +/- 3.66 weeks) and final survival rate (9/35 mice). In an adjusted set of experiments, reducing the IFN concentration to 10,000 and 5,000 units and that of butyrate to 6 mM greatly improved the results. The MST was substantially increased with the combinations of CP + IFN + butyrate (41.4 +/- 1.86 weeks), CP + IFN (42.73 +/- 3.29 weeks) and butyrate + IFN (41 +/- 2.34 weeks), as well as the final survival rates (8/15, 10/15 and 6/15 mice respectively). An important finding was that when CP and IFN were used separately, they were ineffective. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text